Celcuity Announces FDA Approval Of Revtorpyk™ (Gedatolisib) For The Treatment Of Hr+/Her2-, Pik3ca Wild-Type Locally Advanced Or Metastatic Breast Cancer - CELC News | Rallies
Celcuity Announces FDA Approval Of Revtorpyk™ (Gedatolisib) For The Treatment Of Hr+/Her2-, Pik3ca Wild-Type Locally Advanced Or Metastatic Breast Cancer
FDA approves Revtorpyk for breast cancer treatment
Celcuity Inc. announced FDA approval of Revtorpyk™ (gedatolisib) for the treatment of HR+/HER2-, PIK3CA wild-type locally advanced or metastatic breast cancer.
Celcuity anticipates a Revtorpyk commercial launch in late Q3 2026.
The company said it will submit sNDAs for Revtorpyk in HR+/HER2-, PIK3CA mutated breast cancer in Q3 2026.
CELC•
